MENU
×
×
×
PRODUCTS
    ARTICLES
      No results
      found!

      SIGN IN TO YOUR ACCOUNT

      Already registered?
      If you are a registered user, please enter your email and password

      Invalid email or password

      OR
      FORGOT PASSWORD?
      CREATE NEW ACCOUNT

      REGISTER

      Create your account so you can check out faster, save multiple shipping addresses and more.
      {{firstNameError}}
      {{lastNameError}}
      {{emailError}}
      {{passwordError}}
      {{passwordConfirmationError}}
      OR
      ALREADY HAVE AN ACCOUNT? SIGN IN

      FORGOT YOUR PASSWORD?

      Enter your email and we will send you instructions...
      ALREADY HAVE AN ACCOUNT? SIGN IN
      Blog bg
      Arriani - DHI Agreement
      Back to articles back to list

      Description

      Arriani Pharmaceuticals S.A. has signed an agreement with DHI Global Medical Group with the aim of identifying the implication of senescence in hair loss and androgenic alopecia. Since 1970, DHI's mission is to contribute to the health and well-being of all patients suffering from hair loss and scalp disorders worldwide through research, education and innovative treatments. To this end, DHI is collaborating with the Laboratory of Histology & Embryology at Medical School of Athens and the Research Group of Professor Vassilis Gorgoulis for the innovative DHI Hair Biology Test. By utilizing SenTraGor™ reagent, the commercial name of GL13 compound, this test will be expanded to include detection of senescence in hair follicles.